GlassScriptPhysician profile
Lance Douglas Clawson
NPI 1114022449
$3,257.32
in general payments reported to CMS, 2019-2025
19 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $54.21 · 2021: $520 · 2022: $328 · 2023: $504 · 2024: $821 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,675 · Education: $57.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,674.87 |
| Education | $57.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $485.77 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $479.71 | 2023-2025 | Caplyta |
| Tris Pharma INC | $361.36 | 2019-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Abbvie INC. | $345.05 | 2023-2025 | Vraylar |
| Sunovion Pharmaceuticals INC. | $301.46 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $258.22 | 2019-2022 | |
| Lundbeck LLC | $233.14 | 2019-2024 | Rexulti, Abilify Asimtufii |
| Otsuka America Pharmaceutical, INC. | $182.40 | 2021-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $165.08 | 2019-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $83.39 | 2023-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $73.60 | 2023-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $70.46 | 2019 | |
| Bausch Health US, LLC | $64.67 | 2025 | Aplenzin |
| Neos Therapeutics, LP | $37.89 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $36.80 | 2021-2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $29.48 | 2019 | |
| Collegium Pharmaceutical, INC. | $22.82 | 2025 | Jornay Pm |
| Arbor Pharmaceuticals, INC. | $14.91 | 2019 | |
| Adlon Therapeutics L.P. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Clawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.